8-K: BioAge BGE-102 Shows Positive Phase 1 Data for Heart Risk

BioAge Labs announced positive interim Phase 1 clinical trial data for BGE-102, a novel NLRP3 inhibitor for cardiovascular risk factors, demonstrating good tolerability, strong target engagement, and high brain penetration.

Summary

• BioAge Labs, Inc. reported positive interim data from its ongoing Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) clinical trial for BGE-102.
• BGE-102 is an orally available, brain-penetrant small molecule NLRP3 inhibitor developed for patients with cardiovascular risk factors.
• The drug was well-tolerated across all evaluated SAD (10, 30, 60, 120 mg) and initial MAD (60, 120 mg) cohorts.
• Adverse events were infrequent, mild to moderate, and resolved without intervention.
• BGE-102 achieved 90-98% suppression of IL-1, a cytokine downstream of NLRP3, at Day 14, indicating strong target engagement.
• Doses of 60 mg and higher demonstrated high brain penetration, exceeding target IC90 levels in cerebrospinal fluid (CSF) at Day 14.
• The pharmacokinetic profile supports once-daily oral dosing.
• The Phase 1 trial is being expanded to include MAD cohorts in participants with obesity and elevated hsCRP, with data expected in the first half of 2026.
• A Phase 2a proof-of-concept study in approximately 100 patients with obesity and cardiovascular risk factors is planned for initiation in 1H26, with data readout anticipated in 2H26.

Sentiment

Score: 8

Explanation: The interim Phase 1 data is overwhelmingly positive, showing good tolerability, strong target engagement, and a key differentiator in brain penetration. This significantly de-risks the early development stage and provides a clear path to Phase 2a, indicating strong progress for the company's lead candidate.

Positives

• BGE-102 was well-tolerated across all dose levels (SAD: 10, 30, 60, 120 mg; MAD: 60, 120 mg) evaluated to date.
• Adverse events were infrequent and mild to moderate in severity, resolving without intervention.
• The pharmacokinetic profile supports convenient once-daily oral dosing.
• Demonstrated strong target engagement with 90-98% suppression of IL-1 production at Day 14.
• Achieved high brain penetration, with doses of 60 mg and higher exceeding target IC90 levels in cerebrospinal fluid (CSF) at Day 14, a key differentiator from other NLRP3 inhibitors.
• Dose proportionality was observed across tested doses.

Risks

• The company's ability to develop, obtain regulatory approval for, and commercialize its product candidates, including BGE-102.
• The timing and results of preclinical studies and clinical trials.
• The risk that positive results in early-stage clinical trials may not be replicated in subsequent trials or predictive of results in later-stage trials.
• Risks associated with clinical trials, including managing activities, unexpected concerns from additional data, regulatory authorities requiring more information or delaying/failing to approve drug candidates.
• The occurrence of adverse safety events.
• Failure to protect and enforce intellectual property and other proprietary rights.
• Failure to successfully execute or realize the anticipated benefits of strategic and growth initiatives.
• Risks relating to technology failures or breaches.
• Dependence on collaborators and other third parties for product development and other business aspects, which are outside the company's full control.
• Risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to tariffs and trade barriers.
• Risks associated with current and potential future healthcare reforms.
• Risks relating to attracting and retaining key personnel.
• Changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration.
• Risks relating to access to capital and credit markets.
• Other risks and uncertainties detailed in the company's Quarterly Report on Form 10-Q filed on November 6, 2025, and other SEC filings.

Future Outlook

The company plans to complete the expanded Phase 1 MAD cohorts in obese participants with elevated hsCRP in the first half of 2026, with data evaluating changes in inflammatory biomarkers. Following this, they anticipate initiating a Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in the first half of 2026, targeting approximately 100 patients over 12 weeks with a primary endpoint of percent change in hsCRP. A data readout for the Phase 2a study is expected in the second half of 2026.

Management Comments

• Kristen Fortney, PhD, CEO and co-founder of BioAge, stated: "We're very encouraged by the interim data from our ongoing Phase 1 trial of BGE-102, an NLRP3 inhibitor with best-in-class potential. Once-daily doses of 60 mg and above were well tolerated and exceeded target IC90 levels in both the periphery and the brain."
• Kristen Fortney also highlighted: "The clear evidence of high brain penetration is especially important, as it supports BGE-102's potential to comprehensively target NLRP3-driven inflammation in both the central nervous system and peripheral tissues."
• Paul Rubin, MD, Chief Medical Officer of BioAge, commented: "Recent clinical experience has shown that NLRP3 inhibitors can achieve substantial reductions in inflammatory biomarkers such as hsCRP within the first week of treatment."
• Paul Rubin further noted: "Because IL-1 is a key upstream regulator of CRP production, the potent and sustained IL-1 suppression we observed with BGE-102 has the potential to translate directly into meaningful effects on hsCRP. As a result, we have expanded the current trial with additional cohorts of obese participants with elevated baseline inflammation with the goal of providing early potential biomarker proof-of-concept."

Industry Context

The announcement positions BGE-102 as a potentially differentiated NLRP3 inhibitor, a class of drugs gaining attention for targeting age-related inflammation implicated in various diseases, including cardiovascular and metabolic disorders. The emphasis on high brain penetration is a key differentiator, suggesting a broader therapeutic potential compared to inhibitors that primarily target peripheral inflammation. The expansion into obese participants with elevated hsCRP aligns with the growing focus on addressing inflammation as a core component of metabolic and cardiovascular disease management.

Comparison to Industry Standards

• Management suggests BGE-102 has 'best-in-class potential' among NLRP3 inhibitors.
• The high brain penetration of BGE-102 is highlighted as a 'key differentiator from other NLRP3 inhibitors in development,' enabling targeting of both peripheral and central inflammation.
• The company notes that 'recent clinical experience has shown that NLRP3 inhibitors can achieve substantial reductions in inflammatory biomarkers such as hsCRP within the first week of treatment,' implying BGE-102's potent IL-1 suppression could lead to similar or superior effects on hsCRP.

Stakeholder Impact

• Shareholders: Positive interim data and clear advancement to Phase 2a could increase investor confidence and potentially the company's valuation.
• Patients with cardiovascular risk factors/obesity: BGE-102 shows promise as a novel therapeutic option with a unique mechanism of action, potentially offering a new treatment pathway.
• Employees: Continued positive clinical development supports job security and potential growth opportunities within the company.
• Regulatory authorities: Positive early-stage data provides a strong foundation for future regulatory submissions and discussions.

Next Steps

• Complete Phase 1 MAD cohorts in obese participants with elevated hsCRP in 1H26.
• Evaluate changes in key inflammatory biomarkers including hsCRP and IL-1 from expanded Phase 1 cohorts.
• Initiate Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in 1H26.
• Enroll approximately 100 patients for the Phase 2a trial, randomized 1:1 to placebo or BGE-102 monotherapy for 12 weeks.
• Assess percent change in hsCRP as the primary endpoint in the Phase 2a trial, along with other inflammatory and metabolic biomarkers and MRI imaging.
• Provide Phase 2a data readout in 2H26.

Key Dates

Recommendation

The positive interim Phase 1 data for BGE-102, demonstrating excellent tolerability, strong target engagement, and crucially, high brain penetration, significantly de-risks the lead asset. The clear path to Phase 2a initiation and subsequent data readout within the next year provides tangible milestones. The 'best-in-class potential' and unique brain-penetrant profile differentiate BGE-102 in the competitive NLRP3 inhibitor space, addressing a large market of cardiovascular risk factors in obesity. This strong early clinical validation warrants a 'buy' recommendation for long-term investors, given the promising therapeutic profile and clear development trajectory.

Keywords

BGE-102, NLRP3 inhibitor, cardiovascular risk factors, obesity, Phase 1 clinical trial, interim data, brain-penetrant, IL-1 suppression, hsCRP, biopharmaceutical, metabolic diseases, aging biology, clinical-stage